– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal canal dimensions observed with TransCon CNP and TransCon hGH combination therapy compared to
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis